Investigational drug · Phase 3
SBP-101
Also called: ivospemin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SBP-101"
First trial start
2022
Aug 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SBP-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer Metastatic
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer Stage IV
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SBP-101" as an intervention, largest first.
- Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPivotal-lookingRecruiting
Panbela Therapeutics, Inc.Industry
NCT05254171 · 600 participants (planned) · Start Aug 8, 2022 · Primary completion Aug 29, 2026
Drug: SBP-101; Nab-paclitaxel and 1 more · For: Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV
Sites: Hot Springs, Arkansas; Fullerton, California; New Haven, Connecticut · 93 sites in all
Panbela Therapeutics, Inc.Industry
NCT03412799 · 50 participants · Start Jun 4, 2018 · Primary completion Feb 28, 2022
Drug: SBP-101; nab-paclitaxel and 1 more · For: Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Stage IV Pancreatic Cancer
Sites: La Jolla, California; Gainesville, Florida; Rochester, New York · 7 sites in all
Panbela Therapeutics, Inc.Industry
NCT02657330 · 29 participants · Start Jan 2016 · Primary completion Oct 2017
Drug: SBP-101 · For: Pancreatic Cancer; Ductal Adenocarcinoma of the Pancreas
Sites: Scottsdale, Arizona; Kurralta Park, Australia; Heidelberg, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- When Does Rebleeding Occur in Subarachnoid Hemorrhage? Revisiting Rebleeding Cases with a Focus on Blood Pressure.
Kobata H, Tucker A, Sarapuddin G, et al. · World Neurosurg 2026
- RETINAL TOXICITY ASSOCIATED WITH NAB-PACLITAXEL AND GEMCITABINE WITH SBP-101.
Zhou AZ, Oh JK, Tsang SH, et al. · Retin Cases Brief Rep 2026
- Retinal toxicity following SBP-101 combined with gemcitabine and nab-paclitaxel chemotherapy.
Driouich Z, Younis S, Ali AHG · J Fr Ophtalmol 2026
- Progressive Bilateral Retinal Pigment Epithelium Atrophy Associated With SBP-101 (Ivospemin) for Pancreatic Cancer: A Case Report.
Stalmashka T, Coco Martín RM · Ophthalmic Surg Lasers Imaging Retina 2026
- Hemodynamic effects of red blood cell transfusion in patients with hemato-oncologic diseases.
Yazdani B, Schneider N, Abba M, et al. · Front Med (Lausanne) 2026
- Rapidly progressive central retinal pigmented epithelium atrophy after Ivospemin (SBP-101) treatment for pancreatic adenocarcinoma.
Carlà MM, Mateo C · Am J Ophthalmol Case Rep 2024
Also in development for Pancreatic Cancer Metastatic
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- PelareorepPhase 23 trials
Oncolytics Biotech · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic
- TNG462Phase 23 trials
Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC
- ERAS-0015Phase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
- narmafotinibPhase 21 trial
Amplia Therapeutics Limited · Pancreatic Cancer Metastatic
- vopimetostatPhase 21 trial
Tango Therapeutics, Inc. · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.